Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma

European Journal of Cancer

Volumn 47, Issue 5, 2011, Pages 690-696

  Busse, Antonia ^a   Asemissen, Anne Marie ^a,b   Nonnenmacher, Anika ^a   Braun, Floriane ^a,c   Ochsenreither, Sebastian ^a   Stather, David ^a   Fusi, Alberto ^a   Schmittel, Alexander ^a   Miller, Kurt ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Medicine II (Hematology and Oncology)   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Interleukin 10; Regulatory T cells; Renal cell carcinoma; Sorafenib; Transforming growth factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MALE; METASTASIS; MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PYRIDINES; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79952101899     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.11.021     Document Type: Article

References (33)

1. C. Coppin, F. Porzsolt, and A. Awa Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 1 2005 CD001425 [online]
2. G.B. Lesinski, M. Anghelina, and J. Zimmerer The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse J Clin Invest 112 2 2003 170 180 (Pubitemid 38056353)
3. B. Badgwell, G.B. Lesinski, and C. Magro The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line J Surg Res 116 1 2004 129 136 (Pubitemid 38083295)
4. D.F. McDermott Immunotherapy of metastatic renal cell carcinoma Cancer 115 10 Suppl 2009 2298 2305
5. Romo de Vivar Chavez A, de Vera ME, Liang X, Lotze MT. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Med Oncol (Northwood, London, England) 2009;26(Suppl 1):3-12.
6. B. Seliger Immune escape mechanisms of renal cell carcinoma Eur Urol Suppl 6 2007 616 622 (Pubitemid 46618138)
7. J. Bellmunt Future developments in renal cell carcinoma Ann Oncol 20 Suppl 1 2009 i13 i17
8. J. Bellmunt, P. Flodgren, J. Roigas, and S. Oudard Optimal management of metastatic renal cell carcinoma: an algorithm for treatment BJU Int 104 1 2009 10 18
9. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
10. S. Wilhelm, C. Carter, and M. Lynch Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 10 2006 835 844 (Pubitemid 44480537)
11. J.C. Yang, and R. Childs Immunotherapy for renal cell cancer J Clin Oncol 24 35 2006 5576 5583 (Pubitemid 46631338)
12. A. Busse, and U. Keilholz Immune self-tuning in renal cell carcinoma Eur Oncol 6 1 2009 70 75
13. C. Porta, C. Paglino, I. Imarisio, and L. Bonomi Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents Scientific World J 7 2007 837 849
14. C.W. Ryan, B.H. Goldman, and P.N. Lara Jr. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 22 2007 3296 3301 (Pubitemid 47325615)
15. J.A. Gollob, W.K. Rathmell, and T.M. Richmond Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 22 2007 3288 3295 (Pubitemid 47325614)
16. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 1 2008 127 132
17. K.R. Molhoek, C.C. McSkimming, W.C. Olson, D.L. Brautigan, and C.L. Slingluff Jr. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2 Cancer Immunol Immunother 58 6 2009 867 876
18. W. Zhao, Y.H. Gu, R. Song, B.Q. Qu, and Q. Xu Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation Leukemia 22 6 2008 1226 1233 (Pubitemid 351833791)
19. R. Houben, H. Voigt, and C. Noelke MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib Mol Cancer Ther 8 2 2009 433 440
20. M.M. Hipp, N. Hilf, and S. Walter Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses Blood 111 12 2008 5610 5620
21. C. Alfaro, N. Suarez, and A. Gonzalez Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes Br J Cancer 100 7 2009 1111 1119
22. P. Therasse Measuring the clinical response. What does it mean? Eur J Cancer 38 14 2002 1817 1823 (Pubitemid 35256090)
23. J.M. Siehl, E. Thiel, and K. Heufelder Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias Br J Haematol 123 2 2003 235 242 (Pubitemid 37305057)
24. A. Busse, A. Asemissen, and A. Nonnenmacher Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-beta 1 mRNA expression in peripheral blood mononuclear cells J Immunother 34 1 2011 113 119
25. G.C. Cesana, G. DeRaffele, and S. Cohen Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 7 2006 1169 1177 (Pubitemid 46638815)
26. J.H. Finke, B. Rini, and J. Ireland Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 20 2008 6674 6682
27. M.A. Fabian, W.H. Biggs 3rd, and D.K. Treiber A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 3 2005 329 336 (Pubitemid 41094421)
28. J.S. Ko, A.H. Zea, and B.I. Rini Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 6 2009 2148 2157
29. M. Krusch, J. Salih, and M. Schlicke The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro J Immunol 183 12 2009 8286 8294
30. C. Sers, R. Kuner, and C.S. Falk Down-regulation of HLA class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells Int J Cancer 125 7 2009 1626 1639
31. H. Sumimoto, F. Imabayashi, T. Iwata, and Y. Kawakami The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 203 7 2006 1651 1656 (Pubitemid 44036269)
32. Amagai Y, Matsumoto M, Hojo K, et al. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. Jpn J Clin Oncol 2010;40(6):503-7.
33. M. Iguchi, M. Matsumoto, and K. Hojo Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma Jpn J Clin Oncol 39 5 2009 303 309